<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cogent Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/cogent-biosciences-inc</link>
<description>Latest news and press releases for Cogent Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cogent-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835581478dffbe2df0ea73d.webp</url>
<title>Cogent Biosciences Inc</title>
<link>https://6ix.com/company/cogent-biosciences-inc</link>
</image>
<item>
<title>Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-oral-presentation-of-positive-phase-3-peak-trial-in-gastrointestinal-stromal-tumors-gist-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-oral-presentation-of-positive-phase-3-peak-trial-in-gastrointestinal-stromal-tumors-gist-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting</guid>
<pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass. and BOULDER, Colo., April 21, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing</description>
</item>
<item>
<title>Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-poster-presentations-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-poster-presentations-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026</guid>
<pubDate>Fri, 17 Apr 2026 12:00:00 GMT</pubDate>
<description>– Updated presentation on Cogent’s potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors – Updated presentation on Cogent’s brain penetrant ErbB2 inhibitor, CGT4255, with evidence of synergistic activity in combination with HER2 ADCs for resistant patients WALTHAM, Mass. and BOULDER, Colo., April 17, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company foc</description>
</item>
<item>
<title>Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-submission-of-new-drug-application-for-bezuclastinib-in-gastrointestinal-stromal-tumors-gist</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-submission-of-new-drug-application-for-bezuclastinib-in-gastrointestinal-stromal-tumors-gist</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing</description>
</item>
<item>
<title>Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-for-bezuclastinib-in-patients-with-nonadvanced-systemic-mastocytosis-nonadvsm</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-for-bezuclastinib-in-patients-with-nonadvanced-systemic-mastocytosis-nonadvsm</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>NDA based on positive clinical results from the SUMMIT pivotal trial in which bezuclastinib demonstrated clear clinical benefit across all symptom domains</description>
</item>
<item>
<title>Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-highlights-additional-data-with-six-bezuclastinib-posters-from-summit-trial-at-2026-aaaai-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-highlights-additional-data-with-six-bezuclastinib-posters-from-summit-trial-at-2026-aaaai-annual-meeting</guid>
<pubDate>Sat, 28 Feb 2026 05:00:00 GMT</pubDate>
<description>Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients</description>
</item>
<item>
<title>Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-reports-recent-business-130000304</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-reports-recent-business-130000304</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026PEAK NDA initiated for bezuclastinib in patients with 2L GIST under Real-Time Oncology Review (RTOR) and Breakthrough Therapy Designation (BTD); completion of NDA on track for April 2026Six abstracts from SUMMIT trial of bezuclastinib in patients with NonAdvSM accepted for presentation at 2026 AAAAI annual meetingStrong financial posi</description>
</item>
<item>
<title>Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-multiple-summit-130000851</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-multiple-summit-130000851</guid>
<pubDate>Tue, 10 Feb 2026 13:00:00 GMT</pubDate>
<description>WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced multiple upcoming posters highlighting bezuclastinib results from the SUMMIT trial in NonAdvanced Systemic Mastocytosis (NonAdvSM) patients at the 2026 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in Philadelphia, PA, February 27-March 2</description>
</item>
<item>
<title>Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-breakthrough-therapy-designation-bezuclastinib</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-breakthrough-therapy-designation-bezuclastinib</guid>
<pubDate>Mon, 26 Jan 2026 05:00:00 GMT</pubDate>
<description>- Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026</description>
</item>
<item>
<title>Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-initiate-drug-application-130000221</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-initiate-drug-application-130000221</guid>
<pubDate>Tue, 20 Jan 2026 13:00:00 GMT</pubDate>
<description>- PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and ORR of 46% in patients who had received prior treatment with imatinib - Cogent is expected to initiate the RTOR process immediately; completion of the PEAK NDA submission expected in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT)</description>
</item>
<item>
<title>Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) </title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-initiate-new-drug-application-nda-submission-bezuclastinib-under</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-initiate-new-drug-application-nda-submission-bezuclastinib-under</guid>
<pubDate>Tue, 20 Jan 2026 05:00:00 GMT</pubDate>
<description>- PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib</description>
</item>
<item>
<title>Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-anticipated-2026-commercial-and-clinical-milestones</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-anticipated-2026-commercial-and-clinical-milestones</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April</description>
</item>
<item>
<title>Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-presentation-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-presentation-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass. and BOULDER, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing</description>
</item>
<item>
<title>Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-submission-new-drug-application-bezuclastinib</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-submission-new-drug-application-bezuclastinib</guid>
<pubDate>Tue, 30 Dec 2025 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing</description>
</item>
<item>
<title>Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-positive-top-line-results-apex-trial-bezuclastinib</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-positive-top-line-results-apex-trial-bezuclastinib</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG</description>
</item>
<item>
<title>Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-presents-full-summit-results-bezuclastinib-patients-nonadvanced</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-presents-full-summit-results-bezuclastinib-patients-nonadvanced</guid>
<pubDate>Sat, 06 Dec 2025 05:00:00 GMT</pubDate>
<description>-- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe</description>
</item>
<item>
<title>Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-participation-jefferies-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-participation-jefferies-global-healthcare-conference</guid>
<pubDate>Fri, 14 Nov 2025 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass. and BOULDER, Colo., May 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing</description>
</item>
<item>
<title>Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-pricing-concurrent-public-offerings-common-stock-and</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-pricing-concurrent-public-offerings-common-stock-and</guid>
<pubDate>Tue, 11 Nov 2025 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass. and BOULDER, Colo., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on</description>
</item>
<item>
<title>Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-proposed-concurrent-public-offerings-convertible-senior</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-announces-proposed-concurrent-public-offerings-convertible-senior</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass. and BOULDER, Colo., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on</description>
</item>
<item>
<title>Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-reports-positive-results-bezuclastinib-peak-phase-3-trial</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-reports-positive-results-bezuclastinib-peak-phase-3-trial</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>16.5 months median progression free survival (mPFS) for bezuclastinib plus sunitinib compared to 9.2 months mPFS for sunitinib monotherapy (HR=0.50, CI:</description>
</item>
<item>
<title>Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-reports-recent-business-140100016</link>
<guid isPermaLink="true">https://6ix.com/company/cogent-biosciences-inc/news/cogent-biosciences-reports-recent-business-140100016</guid>
<pubDate>Mon, 03 Nov 2025 14:01:00 GMT</pubDate>
<description>Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug Application (NDA) filing for NonAdvSM remains on track for year-end 2025 Multiple bezuclastinib abstracts selected for presentation at the 67th Annual Meeting of the American Society of Hematology (ASH); SUMMIT data in NonAdvSM selected for two oral presentations Plan to showcase novel JAK2 V617F muta</description>
</item>
</channel>
</rss>